New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association's 78th Annual Scientific Sessions


TITUSVILLE, N.J., June 8, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a new late-breaking analysis (OBSERVE-4D) examining how INVOKANA® (canagliflozin) and other type 2 diabetes (T2D) therapies are being used by U.S. patients is among the 15 company abstracts accepted for oral and poster presentations at the American Diabetes Association's (ADA) 78th Annual Scientific Sessions from June 22-26, 2018, in Orlando, FL.

OBSERVE-4D is the largest, most comprehensive, retrospective real-world observational study to evaluate the risk of lower extremity amputation and hospitalization for heart failure (HHF) with INVOKANA® and other T2D medications. This study compared the effects of INVOKANA® with other sodium glucose cotransporter 2 inhibitor (SGLT2i) therapies, and non-SGLT2is across a broad U.S. T2D population of more than 700,000 patients. Until this year's ADA meeting, no real-world study has shown direct head-to-head comparative evidence among individual SGLT2i medicines.

Click to Tweet: First read-out of new real-world type 2 #diabetes data to be unveiled at #ADA2018, including late-breaking analysis of more than 700K U.S. patients

"The breadth of this year's accepted data demonstrates our deep commitment to help address the needs of a broad range of type 2 diabetes patients, including those physicians routinely see in clinical practice," said Paul Burton, M.D., Ph.D., Vice President, Janssen Scientific Affairs, LLC. "We look forward to sharing our extensive clinical and real-world INVOKANA® data at the upcoming ADA Scientific Sessions."

In addition to several comparative studies between INVOKANA® and other diabetes medications, including GLP-1s and sitagliptin, Janssen will also share six new analyses of data from the landmark CANVAS Program (CANagliflozin cardioVascular Assessment Study) in people with type 2 diabetes evaluating:

  • Overall long-term safety
  • Cardiovascular and renal-related outcomes in patient groups based on body mass index (obese vs. non-obese), level of blood glucose control (A1C levels), and global geographic regions
  • CV outcomes in patient groups based on kidney function levels

Notable INVOKANA® data accepted at ADA include:

     No.                                 Title                                           Date/Time
     --------                            -----                                           ---------

    Late-Breaking Findings

    This study is embargoed until Sunday, June 24, 2018 at 10:15 am ET.

    4-LB                                  Canagliflozin vs. Other Antihyperglycemic
                                          Agents on the Risk of Below-Knee
                                          Amputation for Patients with T2DM--A
                                          Real-World Analysis of >700,000 U.S.
                                          Patients (OBSERVE-4D)                          Moderated session:

                                                                                       Jun 24, 2018

                                                                                       12:00-1:00 pm ET
    ---                                  ---                                  ----------------

    Oral Presentations

    These data are embargoed until Monday, June 25, 2018 at 8:00 am ET.

    258-OR                                Canagliflozin and Cardiovascular (CV)
                                          Outcomes in Patients with Chronic Kidney
                                          Disease                                        June 25, 2018

                                                                                       9:00 am ET
    ---                                  ---                                  ----------

    259-OR                                Overall Safety of Canagliflozin (CANA) in
                                          the CANagliflozin cardioVascular Assessment
                                          Study (CANVAS) Program                         June 25, 2018

                                                                                       9:15 am ET
    ---                                  ---                                  ----------

    This study is embargoed until Saturday, June 23, 2018 at 8:00 am ET.

    109-OR                                Effect of Combination Therapy With
                                          Liraglutide Plus Canagliflozin on HGP and
                                          HbA1c versus Each Therapy Alone in T2DM        June 23, 2018
                                                                                       5:45 pm ET
    ---                                  ---                                  ----------

    Poster Presentations

    These data are embargoed until Saturday, June 23, 2018 at 10:00 am ET.

    1191-P                                Relatively Consistent Effects of
                                          Canagliflozin (CANA) on Outcomes Regardless
                                          of Baseline HbA1c in the CANagliflozin
                                          cardioVascular Assessment Study (CANVAS)
                                          Program                                        June 24, 2018

                                                                                       12:00-1:00 pm ET
    ---                                  ---                                  ----------------

    1193-P                                Consistent Outcomes With Canagliflozin
                                          (CANA) in Patients With Type 2 Diabetes
                                          Across Geographic Regions: Results from the
                                          CANagliflozin cardioVascular Assessment
                                          Study (CANVAS) Program                         June 24, 2018

                                                                                       12:00-1:00 pm ET
    ---                                  ---                                  ----------------

    1206-P                                Improved Cardiovascular and Renal Outcomes
                                          in the CANagliflozin cardioVascular
                                          Assessment Study (CANVAS) Program
                                          Irrespective of Baseline (BL) Body Mass
                                          Index (BMI)                                    June 24, 2018

                                                                                       12:00-1:00 pm ET
    ---                                  ---                                  ----------------

    1210-P                                Improvements in Blood Pressure (BP) and
                                          Markers of Arterial Stiffness With
                                          Canagliflozin (CANA) in the CANagliflozin
                                          cardioVascular Assessment Study (CANVAS)
                                          Program                                        June 24, 2018

                                                                                       12:00-1:00 pm ET
    ---                                  ---                                  ----------------

    1126-P                                Systems Medicine Derived Biomarkers to
                                          Assess How Canagliflozin Delays Progression
                                          of Diabetic Kidney Disease                     Moderated session:

                                                                                       June 23, 2018

                                                                                       12:30-1:30 pm ET

                                                                                       General session:

                                                                                       June 24, 2018

                                                                                       12:00-1:00 pm ET
    ---                                  ---                                  ----------------

    1272-P                                Assessing the Value of Canagliflozin (CANA)
                                          versus Sitagliptin (SITA) as 2nd Line
                                          Therapy in the US: The Importance of
                                          Considering Evidence from the CANVAS
                                          Program                                        June 24, 2018

                                                                                       12:00-1:00 pm ET
    ---                                  ---                                  ----------------

    1291-P                                Body Weight (BW) Outcomes With Canagliflozin
                                          300 mg (CANA) vs Glucagon-like Peptide-1
                                          Receptor Agonists (GLP-1s) in a Real-
                                          world (RW) Setting                             June 24, 2018

                                                                                       12:00-1:00 pm ET
    ---                                  ---                                  ----------------

    1287-P                                Real-World Comparative Effectiveness,
                                          Treatment Patterns, and Costs in Type 2
                                          Diabetes Mellitus (T2DM) Patients Initiated
                                          on Canagliflozin 300 mg (CANA) or a
                                          Glucagon-like Peptide-1 Receptor Agonist
                                          (GLP-1)                                        June 24, 2018

                                                                                       12:00-1:00 pm ET
    ---                                  ---                                  ----------------

    1183-P                                Real-world Impact of HbA1c Reduction on
                                          Treatment Intensification and HbA1c Goal
                                          Attainment in T2DM Patients Initiated on
                                          SGLT2i                                         June 24, 2018

                                                                                       12:00-1:00 pm ET
    ---                                  ---                                  ----------------

    1184-P                                CANadian CAnagliflozin REgistry (CanCARE) -
                                          A Prospective, Observational, Assessment of
                                          Canagliflozin (CANA) Treatment in Type 2
                                          Diabetes Mellitus (T2DM); 12 Month Results     June 24, 2018

                                                                                       12:00-1:00 pm ET
    ---                                  ---                                  ----------------

    821-P                                 Relationship Between Weight Change Patterns
                                          and Health Satisfaction in the CANadian
                                          Canagliflozin Registry (CanCARE) Study         June 25, 2018

                                                                                       12:00-1:00 pm ET
    ---                                  ---                                  ----------------

Janssen Pharmaceuticals, Inc. and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation, including in the United States.

INVOKANA® (canagliflozin) is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. INVOKANA® is not for people with type 1 diabetes or with diabetic ketoacidosis (increased ketones in blood or urine). It is not known if INVOKANA® is safe and effective in children under 18 years of age. The recommended starting dose is 100 mg once daily, taken before the first meal of the day. The dose can be increased to 300 mg once daily in patients tolerating INVOKANA® 100 mg once daily who have an eGFR of 60 mL/min/1.73 m2 or greater and require additional glycemic control.


INVOKANA® (canagliflozin) can cause important side effects, including:

  • Amputations. INVOKANA® may increase your risk of lower-limb amputations. Amputations mainly involve removal of the toe or part of the foot; however, amputations involving the leg, below and above the knee, have also occurred. Some people had more than one amputation, some on both sides of the body. You may be at a higher risk of lower-limb amputation if you: have a history of amputation, have heart disease or are at risk for heart disease, have had blocked or narrowed blood vessels (usually in leg), have damage to the nerves (neuropathy) in the leg, or have had diabetic foot ulcers or sores. Call your doctor right away if you have new pain or tenderness, any sores, ulcers, or infections in your leg or foot. Your doctor may decide to stop your INVOKANA® for a while if you have any of these signs or symptoms. Talk to your doctor about proper foot care
  • Dehydration. INVOKANA® can cause some people to become dehydrated (the loss of too much body water), which may cause you to feel dizzy, faint, lightheaded, or weak, especially when you stand up (orthostatic hypotension). You may be at higher risk of dehydration if you have low blood pressure, take medicines to lower your blood pressure (including diuretics [water pills]), are on a low sodium (salt) diet, have kidney problems, or are 65 years of age or older
  • Vaginal yeast infection. Women who take INVOKANA® may get vaginal yeast infections. Symptoms include: vaginal odor, white or yellowish vaginal discharge (discharge may be lumpy or look like cottage cheese), or vaginal itching
  • Yeast infection of the penis (balanitis or balanoposthitis). Men who take INVOKANA® may get a yeast infection of the skin around the penis. Symptoms include: redness, itching, or swelling of the penis; rash of the penis; foul-smelling discharge from the penis; or pain in the skin around penis

Talk to your doctor about what to do if you get symptoms of a yeast infection of the vagina or penis.

Do not take INVOKANA® if you:

  • are allergic to canagliflozin or any of the ingredients in INVOKANA®. Symptoms of allergic reaction may include: rash; raised red patches on your skin (hives); or swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing
  • have severe kidney problems or are on dialysis

Before you take INVOKANA®, tell your doctor if you have a history of amputation; heart disease or are at risk for heart disease; blocked or narrowed blood vessels (usually in leg); damage to the nerves (neuropathy) of your leg; diabetic foot ulcers or sores; kidney problems; liver problems; history of urinary tract infections or problems with urination; are on a low sodium (salt) diet; are going to have surgery; are eating less due to illness, surgery, or change in diet; pancreas problems; drink alcohol very often (or drink a lot of alcohol in short-term); ever had an allergic reaction to INVOKANA®; or have other medical conditions.

Tell your doctor if you are or plan to become pregnant, are breastfeeding, or plan to breastfeed. INVOKANA® may harm your unborn baby. If you become pregnant while taking INVOKANA®, tell your doctor right away. INVOKANA® may pass into your breast milk and may harm your baby. Do not breastfeed while taking INVOKANA®.

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take diuretics (water pills), rifampin (used to treat or prevent tuberculosis), phenytoin or phenobarbital (used to control seizures), ritonavir (Norvir®, Kaletra® - used to treat HIV infection), or digoxin (Lanoxin® - used to treat heart problems).

Possible Side Effects of INVOKANA®
INVOKANA® may cause serious side effects, including:

  • Ketoacidosis (increased ketones in your blood or urine). Ketoacidosis has happened in people who have type 1 or type 2 diabetes, during treatment with INVOKANA®. Ketoacidosis is a serious condition, which may need to be treated in a hospital. Ketoacidosis may lead to death. Ketoacidosis can happen with INVOKANA® even if your blood sugar is less than 250 mg/dL. Stop taking INVOKANA® and call your doctor right away if you get any of the following symptoms: nausea, vomiting, stomach-area pain, tiredness, or trouble breathing
  • Kidney problems. Sudden kidney injury has happened to people taking INVOKANA®. Talk to your doctor right away if you: 1) reduce the amount of food or liquid you drink, if you are sick, or cannot eat or 2) you start to lose liquids from your body from vomiting, diarrhea, or being in the sun too long
  • A high amount of potassium in your blood (hyperkalemia)
  • Serious Urinary Tract Infections may lead to hospitalization and have happened in people taking INVOKANA®. Tell your doctor if you have signs or symptoms of a urinary tract infection such as: burning feeling while urinating, need to urinate often or right away, pain in the lower part of your stomach (pelvis), or blood in the urine. Some people may also have high fever, back pain, nausea, or vomiting
  • Low blood sugar (hypoglycemia). If you take INVOKANA® with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take INVOKANA®

Signs and symptoms of low blood sugar may include: headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, fast heartbeat, sweating, shaking, or feeling jittery.

Serious allergic reaction. If you have any symptoms of a serious allergic reaction, stop taking INVOKANA® and call your doctor right away or go to the nearest hospital emergency room.

Broken Bones (fractures). Bone fractures have been seen in patients taking INVOKANA®. Talk to your doctor about factors that may increase your risk of bone fracture.

The most common side effects of INVOKANA® include: vaginal yeast infections and yeast infections of the penis; changes in urination, including urgent need to urinate more often, in larger amounts, or at night.

Tell your doctor if you have any side effect that bothers you or that does not go away. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Janssen Scientific Affairs, LLC at 1-800-526-7736.

Please see full Product Information, including Boxed Warning, and Medication Guide for INVOKANA®.

Canagliflozin is licensed from Mitsubishi Tanabe Pharma Corporation.

Trademarks are those of their respective owners.

About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at Follow us on Twitter at @JanssenUS. Janssen Pharmaceuticals, Inc. and Janssen Scientific Affairs, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential benefits and further development of canagliflozin. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Pharmaceuticals, Inc., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's subsequent Quarterly Reports on Form 10-Q, and other filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

View original content:

SOURCE Janssen Pharmaceutical Companies


Back to news